The effect of immunodepletion of antithrombin III on the response of rabbits to Russell's viper venom-induced activation of factor X.
Many years ago it was shown that an infusion of tissue factor (TF) into rabbits causing only limited consumption of factor X and prothrombin resulted in extensive consumption of fibrinogen. More recently it was shown that an injection of a concentration of the factor X-activating fraction of Russell's viper venom (RVV-X) depleting rabbits of factor X resulted in only minimal consumption of both plasma prothrombin and fibrinogen. We report here experiments in which rabbits depleted of antithrombin III (ATIII) to different degrees were infused over 4 hours with a concentration of RVV-X, causing consumption of about 60% of plasma factor X. Similar minimal mean falls in plasma prothrombin and fibrinogen levels were observed in control rabbits given nonimmune goat IgG and in rabbits immunodepleted with goat anti-rabbit ATIII IgG to about 40% of normal plasma ATIII activity. However, if rabbits were immunodepleted to about 10% to 20% of normal plasma ATIII, then mean consumption of prothrombin was increased modestly and, more impressively, mean consumption of plasma fibrinogen was increased markedly. Whereas limited amounts of thrombin generated on the surface of phospholipid vesicles by factor VIIa/ TF can trigger extensive intravascular coagulation in rabbits with normal plasma ATIII levels, limited amounts of thrombin generated by reactions triggered by factor Xa formed in fluid phase did so only after plasma ATIII levels were markedly depleted. A possible reason for this difference is discussed.
Rapaport
S I
SI
Department of Medicine, School of Medicine, University of California at San Diego, La Jolla, USA.
Toneff
T
T
Rimon
A
A
Warn-Cramer
B J
BJ
D000818:Animals; D000990:Antithrombin III / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000276:immunology; D005170:Factor X / Q000032:analysis / Q000187:drug effects* / Q000502:physiology; D005340:Fibrinogen / Q000032:analysis; D007958:Leukocyte Count / Q000187:drug effects; D008074:Lipoproteins / Q000097:blood; D008666:Metalloendopeptidases / Q000494:pharmacology*; D010976:Platelet Count / Q000187:drug effects; D011516:Prothrombin / Q000032:analysis / Q000494:pharmacology; D011817:Rabbits
D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D000990:Antithrombin III; D011516:Prothrombin; D005170:Factor X; D005340:Fibrinogen; D008666:Metalloendopeptidases; C033858:russellysin